- Home
- TCBK vs CVAC Comparison
TCBK vs CVAC Comparison
Compare TCBK & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBK
- CVAC
- Stock Information
- Founded
- TCBK 1975
- CVAC 2000
- Country
- TCBK United States
- CVAC Germany
- Employees
- TCBK N/A
- CVAC N/A
- Industry
- TCBK Major Banks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TCBK Finance
- CVAC Health Care
- Exchange
- TCBK Nasdaq
- CVAC Nasdaq
- Market Cap
- TCBK 1.4B
- CVAC 1.2B
- IPO Year
- TCBK N/A
- CVAC 2020
- Fundamental
- Price
- TCBK $44.23
- CVAC $5.34
- Analyst Decision
- TCBK Buy
- CVAC Hold
- Analyst Count
- TCBK 5
- CVAC 3
- Target Price
- TCBK $48.60
- CVAC $6.83
- AVG Volume (30 Days)
- TCBK 101.0K
- CVAC 450.0K
- Earning Date
- TCBK 10-23-2025
- CVAC 11-12-2025
- Dividend Yield
- TCBK 3.26%
- CVAC N/A
- EPS Growth
- TCBK 5.66
- CVAC N/A
- EPS
- TCBK 3.55
- CVAC 1.01
- Revenue
- TCBK $399,268,000.00
- CVAC $599,540,810.00
- Revenue This Year
- TCBK $9.45
- CVAC N/A
- Revenue Next Year
- TCBK $5.81
- CVAC $23.40
- P/E Ratio
- TCBK $12.46
- CVAC $5.31
- Revenue Growth
- TCBK 3.12
- CVAC 675.15
- 52 Week Low
- TCBK $35.20
- CVAC $2.37
- 52 Week High
- TCBK $51.06
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- TCBK 55.63
- CVAC 41.61
- Support Level
- TCBK $43.09
- CVAC $5.33
- Resistance Level
- TCBK $44.66
- CVAC $5.41
- Average True Range (ATR)
- TCBK 1.18
- CVAC 0.03
- MACD
- TCBK 0.24
- CVAC -0.00
- Stochastic Oscillator
- TCBK 89.81
- CVAC 12.50
About TCBK TriCo Bancshares
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.